Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Laekna, Inc. ( (HK:2105) ) is now available.
Laekna, Inc. has begun recruiting patients in China and has dosed the first subject in a Phase I multiple-dose expansion clinical study of its investigational obesity therapy LAE102, marking a key step in advancing its metabolic disease pipeline. The randomized, double-blind, placebo-controlled trial will enroll 60 overweight or obese participants to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of subcutaneous LAE102 over six months, following encouraging early multi-ascending dose data; if successful, the program could strengthen Laekna’s position in the fast-growing obesity treatment market by offering a precision therapy designed to increase lean mass, reduce fat mass, and potentially complement GLP-1 receptor agonists for higher-quality weight management outcomes.
The most recent analyst rating on (HK:2105) stock is a Buy with a HK$24.16 price target. To see the full list of analyst forecasts on Laekna, Inc. stock, see the HK:2105 Stock Forecast page.
More about Laekna, Inc.
Laekna, Inc. is a biopharmaceutical company focused on discovering and developing innovative therapies, including internally discovered monoclonal antibodies, for metabolic diseases such as obesity. Its pipeline targets mechanisms involved in muscle regeneration and lipid metabolism, with an emphasis on providing precision treatments that improve quality weight control for overweight and obese patients.
Average Trading Volume: 3,867,158
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$6.48B
For a thorough assessment of 2105 stock, go to TipRanks’ Stock Analysis page.